| The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. | |
| | |
MedLine Citation:
|
PMID: 3525009 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The dopamine agonist bromocriptine has been widely used to facilitate pregnancy in hyperprolactinaemic women, with a success rate of 80% in relevant cases. Neither the inappropriate hyperprolactinaemia consequent upon bromocriptine withdrawal after conception nor the relative hypoprolactinaemia caused by treatment throughout gestation appears to affect adversely the course and outcome of pregnancy or the endocrine status of the fetus. No teratogenic effect of bromocriptine has been evidenced in humans, and no disturbances in the physical, psychomotor, and intellectual development of the offspring have been observed. Pituitary-tumor enlargement during closely supervised pregnancies very rarely leads to severe and irreversible complications; both the re-institution of bromocriptine treatment in the event of tumor enlargement and its preventive use throughout pregnancy have been shown to be effective measures. It is interesting, moreover, that a reduction of hyperprolactinaemia, compared with pregestational levels, may be seen after bromocriptine-facilitated pregnancies. |
| | |
Authors:
|
C Weil |
Related Documents
:
|
15667449 - Intracerebroventricular injections of prolactin counteract the antagonistic effect of b... 21122599 - A swedish study of midwives' and nurses' experiences when women are diagnosed with a mi... 6718069 - The fetal adrenal gland: lipid distribution with associated intrauterine hypoxia. 205819 - Differential maternal-fetal response to androgenizing luteoma or hyperreactio luteinalis. 12673099 - Selective fetal hypophysectomy in utero: microsurgical technique and comparisons with h... 576229 - Transient bitemporal hemianopsia during pregnancy after treatment of galactorrhea-ameno... 20101849 - Relationship of serum progesterone (p) level the day after human chorionic gonadotropin... 19936969 - Complement activation and pregnancy failure. 9845399 - Foetal outcome in women with inflammatory bowel disease treated during pregnancy with o... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current medical research and opinion Volume: 10 ISSN: 0300-7995 ISO Abbreviation: Curr Med Res Opin Publication Date: 1986 |
Date Detail:
|
Created Date: 1986-09-17 Completed Date: 1986-09-17 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 172-95 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abnormalities, Drug-Induced
/
etiology Adenoma / pathology, surgery Bromocriptine / adverse effects, therapeutic use* Endocrine Glands / drug effects Female Humans Hyperprolactinemia / blood, drug therapy* Infant Infertility, Female / drug therapy* Pituitary Neoplasms / pathology, surgery Pregnancy / drug effects Pregnancy Complications / chemically induced Pregnancy Complications, Neoplastic / pathology, surgery Prolactin / blood Risk Time Factors |
| Chemical | |
Reg. No./Substance:
|
25614-03-3/Bromocriptine; 9002-62-4/Prolactin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ultrasound monitored hepatic cryosurgery: longevity study on an animal model.
Next Document: Distributions of vimentin and desmin filaments in embryonic cardiac muscle cells in culture.